Johnson & Johnson (NYSE:JNJ)‘s stock had its “market perform” rating reiterated by research analysts at Wells Fargo & Company in a research report issued on Thursday. They presently have a $135.00 price objective on the stock, up from their prior price objective of $132.00. Wells Fargo & Company’s price target would indicate a potential upside of 1.86% from the company’s current price.
Other equities analysts have also recently issued research reports about the stock. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target on the stock in a research report on Thursday, May 18th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $128.00 price target (up previously from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Barclays PLC reaffirmed an “equal weight” rating and issued a $130.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. Finally, J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and raised their price target for the company from $123.64 to $140.00 in a research report on Monday, May 15th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $132.69.
Shares of Johnson & Johnson (NYSE JNJ) opened at 132.54 on Thursday. The stock has a 50 day moving average price of $130.42 and a 200-day moving average price of $122.68. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.00. The company has a market capitalization of $357.04 billion, a price-to-earnings ratio of 22.28 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.77 by $0.06. The company had revenue of $17.77 billion during the quarter, compared to the consensus estimate of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period last year, the business posted $1.68 EPS. On average, equities research analysts expect that Johnson & Johnson will post $7.10 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 13th. Stockholders of record on Tuesday, May 30th were given a dividend of $0.84 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Thursday, May 25th. Johnson & Johnson’s payout ratio is 56.47%.
TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company Reiterates Market Perform Rating for Johnson & Johnson (JNJ)” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.wkrb13.com/markets/2284200/wells-fargo-company-reiterates-market-perform-rating-for-johnson-johnson-jnj.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in Johnson & Johnson during the fourth quarter worth approximately $343,000. Twin Capital Management Inc. raised its position in Johnson & Johnson by 0.7% in the fourth quarter. Twin Capital Management Inc. now owns 246,330 shares of the company’s stock worth $28,380,000 after buying an additional 1,690 shares during the period. Cedar Hill Associates LLC increased its stake in Johnson & Johnson by 1.5% in the fourth quarter. Cedar Hill Associates LLC now owns 4,348 shares of the company’s stock worth $501,000 after buying an additional 64 shares in the last quarter. Highland Private Wealth Management increased its stake in Johnson & Johnson by 5.3% in the fourth quarter. Highland Private Wealth Management now owns 7,435 shares of the company’s stock worth $857,000 after buying an additional 371 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Johnson & Johnson by 24.2% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 651,026 shares of the company’s stock worth $75,005,000 after buying an additional 127,036 shares in the last quarter. Hedge funds and other institutional investors own 66.03% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284200/wells-fargo-company-reiterates-market-perform-rating-for-johnson-johnson-jnj.html
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.